SCHEMBL14770550

SCHEMBL14770550

COc1ccc(C(C)c2nc3cc(Cl)ccc3[nH]2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.40
AMY1A P0DUB6 1/20 0.40
BRS3 P32247 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PTGES O14684 1/20 0.39
ALOX5 P09917 1/20 0.39
LTC4S Q16873 1/20 0.39
ADORA3 P0DMS8 1/20 0.38
ADORA1 P30542 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDGFRB P09619 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2E1 P05181 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C8 P10632 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2B6 P20813 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770549 0.89 ALDH1A1 (0.42) BRS3KDM4EPTGESALOX5LTC4S
SCHEMBL14770697 0.86 MLKL (0.51) FLT3AMY1AGAAKDM4EPDGFRB
SCHEMBL14770492 0.84 AMY1A (0.41) FLT3AMY1AKDM4EPTGESALOX5
SCHEMBL14770613 0.84 FLT3 (0.40) FLT3KDM4EPTGESALOX5LTC4S
SCHEMBL14770535 0.82 MEN1 (0.53) KDM4EPTGESALOX5LTC4SLMNA
SCHEMBL14770519 0.82 MAPK1 (0.38) BRS3PTGESALOX5LTC4SCYP1A2
SCHEMBL14770646 0.82 SCN10A (0.40) KDM4EPTGESALOX5LTC4SLMNA
SCHEMBL14770638 0.81 SCN10A (0.52) KDM4EPTGESALOX5LTC4SLMNA
SCHEMBL14770640 0.81 SCN10A (0.44) PTGESALOX5LTC4SMEN1KMT2A
SCHEMBL14770612 0.81 CFB (0.43) GAAKDM4EPTGESALOX5LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A FLT3 1912/4885AMY1A 4661/4885BRS3 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.